ATRX - Adhera Therapeutics appoints new Chairman of the Board focuses on uplist to Nasdaq

Adhera Therapeutics (OTCPK:ATRX +10.9%) is pleased to announce the appointment of Trond K. Waerness as Chairman of the Co.’s Board of Directors. Mr. Waerness has been serving as a Director at Adhera since April 2021, will be replacing Andrew Kucharchuk, who will remain CEO and Vice-Chairman. The Co. has also nominated Zahed Subhan, who currently serves on Adhera’s Board of Directors, as interim Chief Scientific Officer. “Trond is the ideal Chairman to lead Adhera as we move our lead drug candidates for Type 1 diabetes and Parkinson’s disease into mid-stage clinical trials and work to uplist our company to the NASDAQ exchange.” said Andrew Kucharchuk.

For further details see:

Adhera Therapeutics appoints new Chairman of the Board, focuses on uplist to Nasdaq